

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

Title: A multi-centre service evaluation of the impact of the COVID-19 pandemic on presentation of newly diagnosed cancers and type 1 diabetes in children in the UK

Running title: Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

Group authorship:

COVID-19 Pandemic UK-based Interest Group of Childhood Cancer and Diabetes

Gemma Williams, Ross McLean, Jo-Fen Liu, Timothy Ritzmann, Madhumita Dandapani, Dhurgshaarna Shanmugavadivel, Pooja Sachdev, Mark Brougham, Rod Mitchell, Nicholas T Conway, James Law, Alice Cunningham, Gbemi Ogunnaike, Karen Brougham, Elizabeth Bayman and David A Walker

Corresponding author:

Professor David Walker

Children's Brain Tumour Research Centre, University of Nottingham, Nottingham NG7 2UH

Email: david.walker@nottingham.ac.uk

Tel: (0115) 823 0629

Conflict of interest: None

Funding source: None

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

Group members (names listed in alphabetical order)

Name	Affiliation
Elizabeth Bayman	Department of Paediatric Diabetes and Endocrinology, Royal Hospital for Sick Children, Edinburgh
Karen Brougham	Department of Paediatric Oncology, Royal Hospital for Sick Children, Edinburgh
Mark Brougham	Department of Paediatric Oncology, Royal Hospital for Sick Children, Edinburgh
Nicholas T Conway	Tayside Children's Hospital, NHS Tayside Division of Population Health and Genomics, University of Dundee
Alice Cunnington	Nottingham University Hospitals NHS Trust, Nottingham, UK
Madhumita Dandapani	Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK Nottingham University Hospitals NHS Trust, Nottingham, UK
James Law	Department of Paediatric Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust
Jo-Fen Liu	Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
Ross McLean	University Hospital Wishaw, NHS Lanarkshire
Rod Mitchell	MRC Centre for Reproductive Health, The University of Edinburgh Department of Paediatric Diabetes and Endocrinology, Royal Hospital for Sick Children, Edinburgh
Gbemi Ogunnaike	Nottingham University Hospitals NHS Trust
Timothy A Ritzmann	Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK Nottingham University Hospitals NHS Trust, Nottingham, UK
Pooja Sachdev	Department of Paediatric Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust
Dhurgshaarna Shanmugavadivel	Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
David Walker	Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
Gemma Williams	Paediatric Oncology, Leeds Children's Hospital, Leeds Teaching Hospital NHS Trust

Abstract

Background The COVID-19 pandemic led to changes in patterns of presentation to Emergency Departments (ED). Child health professionals were concerned that this could contribute to the delayed diagnosis of life-threatening conditions, including childhood cancer (CC) and type 1 diabetes (T1DM). Our multicentre, UK-based service evaluation assessed diagnostic intervals and disease severity for these conditions.

Methods We collected presentation route, timing and disease severity for children with newly diagnosed CC in three principal treatment centres, and T1DM in four centres between 1st January - 31st July 2020 and the corresponding period in 2019. We assessed the impact of lockdown on total diagnostic interval (TDI), patient interval (PI), system interval (SI) and disease severity.

Findings For CCs and T1DM, the route to diagnosis and severity of illness at presentation were unchanged across all time periods. Diagnostic intervals for CCs during lockdown were comparable to that in 2019 (TDI 4.6, PI 1.1 and SI 2.1 weeks), except for an increased PI in Jan-Mar 2020 (median 2.7 weeks). Diagnostic intervals for T1DM during lockdown were similar to that in 2019 (TDI 16 vs 15 and PI 14 vs 14 days), except for an increased PI in Jan-Mar 2020 (median 21 days).

Interpretation There is no evidence of diagnostic delay or increased illness severity for CC or T1DM, during the first phase of the pandemic across the participating centres. This provides reassuring data for children and families with these life-changing conditions.

(Word count 236)

Keywords:

COVID-19 Pandemic; Total Diagnostic Interval; Patient Interval; Referral Pathways;

Childhood Cancer; Type 1 Diabetes

Word count: main text 2714 excl references

Research in Context:

Evidence before this study

This project was initiated after the first national lockdown in March 2020 during COVID-19 pandemic in the UK. At the design stage, Medline was searched (with no language limit), using the keywords ((Cancer) OR (neoplasm) OR (Type 1 diabetes mellitus)) AND ((Covid-19) OR (SARS-CoV-2) OR (Pandemics)) AND ((Emergency department attendances) OR (diabetes ketoacidosis) OR (Delayed diagnosis) OR (interval) OR (wait)) to identify publications reporting the impact of the pandemic and public health measures on both overall and paediatric healthcare services. Significant changes in service utilisation in the UK were reported following the commencement of the first lockdown, including a 49% reduction in emergency department attendances in the week following the lockdown; and two adult studies reported that referral via the urgent two-week wait cancer referral diagnoses decreased by 84% from Mar-May and 60% in June 2020. As for Type 1 diabetes (T1DM), a 30 patient UK-study reported an increase in newly diagnosed T1DM during the first six weeks of lockdown. Increased proportions of severe diabetic ketoacidosis (DKA) at presentation were also reported in an Italian survey involving 53 paediatric diabetes centres. Through the search we identified a need for multi-centre, more thorough assessment on referral pathways, time taken from symptom onset to diagnosis, and its association with severity at presentation for children diagnosed with life-changing conditions during the national lockdown.

Added value of this study

Our findings suggest that the first national lockdown in the UK were not associated with delayed diagnosis of childhood cancer or type 1 diabetes at participating centres. This provides reassuring information for children and families with these life-changing conditions.

Implication

We believe that our study can play a key role in allaying parental and professional concern. it is important to establish whether subsequent public health measures have impacted the diagnostic interval in the context of an evolving backlog of patient referrals across the UK.

INTRODUCTION

The UK public health response to the COVID-19 pandemic led to major changes in service utilisation of Emergency Departments (ED), with an observed 49% reduction in attendances in the week following the March 2020 announcement of lockdown.¹ More specifically, this reduction was also seen in children's ED attendances in both Scotland and Italy^{2,3}. This raised concern amongst child health professionals that the pandemic could be associated with delayed presentation of children with significant illnesses⁴ including life-changing childhood conditions such as type 1 diabetes (T1DM) and childhood cancer (CC). We were concerned there may have been an increase in delays in seeking medical advice (the patient interval – PI) and/or accessing initial investigations and interventions (the system interval – SI), leading to a prolongation of the total diagnostic interval (TDI).⁵

In the UK, 1900 children are diagnosed with cancer each year^{6,7}. The diverse and often insidious nature of presenting symptoms, combined with the low incidence and lack of awareness of childhood malignancy may contribute to a prolongation of the TDI. Recent adult studies^{8,9} report that referrals via the urgent two-week wait pathway for suspected cancer diagnoses decreased by 84% from March-May 2020⁹ and 60% in June 2020.⁸ One study predicted a reduction of over 10% in 10 year survival of adults with cancer⁹ whilst another predicted an excess of 1307 cancer deaths.⁸ The evidence is equivocal as to whether delays in time to diagnosis impact upon survival from CCs⁹⁻¹¹, however the impact of psychological and economic distress on families awaiting a CC diagnosis should not be underestimated¹⁰.

Experience of the COVID-19 pandemic for children with T1DM has been inconsistent. A survey of 53 Italian paediatric diabetes centres found that the number of children with a new diagnosis of diabetes from February-April 2020 was 23% lower than the corresponding period in 2019. The survey also found the proportion of patients presenting with severe diabetic ketoacidosis (DKA) was increased¹². A 30 patient UK-study reported an apparent increase in new-onset T1DM during the first six weeks of lockdown¹³.

The aim of the project was to assess any impact of the COVID-19 pandemic on new diagnoses of CC and T1DM at participating UK centres.

METHODS

Study Design

We undertook a multicentre service evaluation using existing clinical case data assessing the route of diagnosis, diagnostic interval and severity of presentation.

Eligibility criteria were:

- (1) All children who attended three centres (the Royal Hospital for Sick Children Edinburgh, Leeds Teaching Hospitals NHS Trust and Nottingham University Hospitals NHS Trust) and were diagnosed with cancer between 1st January and 30th June 2019 and the corresponding period in 2020;
- (2) All children who attended four centres (the Royal Hospital for Sick Children, Edinburgh (RHSC), Nottingham University Hospital NHS Trust (NUH), University Hospital Wishaw (UHW) and Ninewells Hospital, Dundee and were diagnosed with T1DM between 1st January-31st July 2019 and the corresponding period in 2020.

Whilst analyses were prospectively designed, a standard proforma (online supplementary material) was used to retrospectively collect information on demographics, diagnosis, referral pathway and clinical presentation. We also collected information on whether patients were shielding at presentation (following specific government guidelines to minimise risk of SARS-CoV-2 exposure for those considered clinically extremely vulnerable). Dates of symptom onset, first presentation to healthcare and final diagnosis were used to calculate total diagnostic interval (TDI, time between symptom onset to diagnosis), patient interval (PI, time between symptom onset to first presentation) and system interval (SI, time between first presentation to diagnosis)⁵

The protocol was approved by Caldicott Guardians of all centres involved.

Statistical analysis

Descriptive analyses, χ^2 test, Mann-Whitney U or Kruskal-Wallis tests were used to describe

patterns of referral and illness, comparing the differences of key measures among different time periods (1st January -31st March 2020, and 1st April-31st July 2020, and the corresponding period in 2019). Pair-wise comparisons of proportions were carried out using the Z test with Bonferroni corrections. All analyses were performed with IBM SPSS 26.0 for Windows (IBM Corp. Armonk, NY, USA) and $p < 0.05$ was considered statistically significant.

RESULTS

Study population

Childhood Cancer

There were 253 new diagnoses of childhood cancer during the study period (Table 1). Of these, 164 (64%) were male and 55 (22%) were from a BAME background. Patients were diagnosed at one of three principal treatment centres (Edinburgh=64, Leeds=100, Nottingham=89). There were no differences in gender, ethnic background or age at diagnosis between study periods (Table 1). The proportion of tumour type in each evaluation period did not change. 95% (53/56) of those who presented during the lockdown period were not shielding.

Overall there was a 17% reduction in number of incident childhood cancer cases between 2019 ($n=138$) and 2020 ($n=115$). This change varied between centres (4% increase to 40% reduction) (Figure 1).

Type 1 Diabetes

There were 187 new diagnoses of T1DM during the study period (Table 2). Of these, 90 (48%) were male and 18 (10%) were from a BAME background. Patients were diagnosed at one of four participating centres (Edinburgh=45, Dundee=30, Wishaw=53, Nottingham=59). There were no differences in gender, ethnic background or age at diagnosis between the study periods (Table 2). 91% (42/46) of those who presented during the lockdown period were not shielding.

A reduction in the numbers of new cases of T1DM between the months of Apr-Jul 2020 and the identical period in 2019 occurred in three of the four units. Overall, there was a 3-24%

reduction in new diagnoses of T1DM between the months of Jan-Jul 2020 compared with the corresponding period in 2019 in all centres ([Figure 1](#)).

Route to diagnosis

Childhood Cancer

Across all time points, 60% of children (152/253) were diagnosed within three or fewer healthcare contacts, 25% within four to six contacts, 8% within seven to nine contacts and 6% required more than 10 contacts prior to diagnosis. There was no difference in distribution across three time periods ($p=0.569$) or Jan-Mar 2020 and Apr-Jun 2020 ($p=0.359$). ([Figure S1a](#)). General practice was the first point of healthcare contact in the majority of patients across all time periods (54% 2019, 49% Jan-Mar 2020, 48% Apr-Jun 2020) ([Figure S1b](#)). 63% of patients presented to hospital as an emergency presentation either from Primary Care or to the ED. 36% of children had their diagnostic investigation requested as an inpatient. These proportions were consistent across all three time periods ($p=0.405$) ([Figure S1c](#)).

Type 1 Diabetes

The source of referral leading to diagnosis was the ED in 30% (14/46) of cases between Apr-Jul 2020. This compared with 12% (5/43) of cases diagnosed between Jan-Mar 2020 ($p=0.091$), and 19% (19/98) of cases diagnosed over the period of Jan-Jul 2019 ($p=0.426$). 63% of patients had been referred by their GP between Apr-Jul 2020, compared with 81% of patients in the preceding three months, and 72% of patients in 2019 ([Figure S2](#)).

Time to diagnosis

Childhood Cancer

Across all three centres, there was no difference in TDI between 2019 and Jan-Mar 2020 or Apr-Jun 2020 ($p=0.351$) ([Figure 2](#), [Figure S3a](#)). There was a significant increase in PI between 2019 and Jan-Mar 2020 (median 0.9 vs 2.7 weeks, $p=0.005$), but during Apr-Jun 2020 there was no difference compared with 2019 (median 1.1 vs 0.9 weeks, $p=0.383$) ([Figure 2](#)). SI was stable across all time points ([Figure 2](#)). There was no difference in TDI across all time periods for leukaemias, CNS tumours and solid tumours in subgroup analyses ([Figure 3](#)). There was

no difference in PI or SI for individual principal treatment centres or tumour types (Figures 3 and Figure S3b-c).

Type 1 Diabetes

Median TDI for incident T1DM cases was 16, 21 and 15 days for 2019, Jan-Mar 2020 and Apr-Jul 2020 respectively. There was no difference across the three time periods ($p=0.119$). A similar pattern was observed in patient interval. The comparison across all time periods was close to significance ($p=0.054$), sub-analyses showed that PI was longer during Jan-Mar 2020 compared to Apr-Jul 2020 (median 21 vs 14 days, $p=0.025$) and 2019 (median 14 days, $p=0.036$) (Figure 4 and Figure S4).

Severity of Presentation

Childhood Cancer

Within seven days of diagnosis, 10% (26/253) of patients with childhood cancer required admission to paediatric intensive care. This was stable across all time periods ($p=0.275$) (Table 1).

Type 1 Diabetes

The proportion of patients presenting in DKA was 41% (19/46) in the period Apr-Jul 2020, 40% (17/43) for the time period Jan-Mar 2020, and 39% (38/98) for the time between Jan-Jul 2019. There was no difference in the proportion of patients in DKA across all time periods. The proportion of children presenting with severe DKA ($\text{pH} < 7.1$, serum bicarbonate $< 5 \text{ mmol/L}$)¹⁴ had non-significantly increased between lockdown (22%, 10/46) compared with 12% (5/43) Jan-Mar 2020 and 13% (13/98) Jan-Jul 2019) in the periods prior to lockdown. There was no significant difference in the rate of intensive care admission or requirement for ventilatory support (Table 2).

DISCUSSION

We have demonstrated that the first phase of the COVID-19 pandemic was not associated with adverse impact on route of presentation, TDI or disease severity at presentation for children with a new diagnosis of CC or T1DM at the study centres. Given the reported

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

reduction in paediatric ED attendance,^{15,16} it had been predicted that both the PI and TDI would be prolonged, and clinical presentations more severe. This prediction was not supported by our study.

A snapshot survey was commissioned in April 2020 by the ChildCancerSmart Team in conjunction with the Childhood Cancer and Leukaemia Group (CCLG) to obtain the absolute numbers of new diagnoses of childhood cancer at each principal treatment centre in the UK (online supplementary material). This survey revealed 27% fewer new cases in April 2020 compared with April 2019, raising concerns about the potential for diagnostic delay. Similar anxieties had been expressed related to delayed presentation of patients with T1DM.¹⁷ One survey of diabetes units in the UK reported that 20% of children and young people diagnosed with T1DM between 1 March and 30 June 2020 had had a delayed presentation. Reasons for this included fear of contracting SARS-CoV-2 as well as limited access to GP services.¹³

We demonstrated higher PI during Jan-Mar 2020 for patients with CC and T1DM. This may reflect a period of uncertainty for patients and health care systems in preparation for the first phase of the pandemic. The subsequent reduction in PI during and after lockdown suggests no significant delay in caregivers seeking medical attention for children, which may reflect contemporary public health messaging.

A study of the North-West London Paediatric Diabetes Network between 23 March and 4 June 2020 reported an apparent increase in cases of new-onset T1DM in two of five units¹³. 21/30 children with a new diagnosis presented with DKA, 52% of which were severe. These are generally considered to represent high rates both of DKA and severe DKA in newly diagnosed patients. However, the number of children involved in this study was small, no comparisons were possible with other time periods and we were unable to replicate the findings.

In a large survey of 53 Italian paediatric diabetes centres, the number of newly diagnosed children with T1DM and DKA were similar to 2019¹². However the proportion of all T1DM patients who developed severe DKA was significantly greater in 2020 (44.3% v 36.1%,

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

$p=0.03$)¹². Despite not being significant, the pattern of our results are similar to the Italian experience¹² which demonstrated a 9% reduction in new diagnoses of T1DM when comparing Jan-Jul 2020 to 2019. Our data showed a 7-44% reduction in three of the four months following lockdown in new cases of T1DM, with a 27% decrease during March 2020 when national lockdown was announced. The incidence of DKA at presentation was stable between the measured time periods, however the incidence of severe DKA was slightly worse following lockdown (22% (Apr-Jul 2020), v 12% (Jan-Mar 2020) v 13% (Jan-Jul 2019)).

The increased incidence of severe DKA amongst patients diagnosed post-lockdown, whilst not significant, is a potential concern. This finding is consistent with the Italian data and with other units in the UK^{12,17}. It initially appears to be counter-intuitive when one takes into account the reduction in the TDI and PI post-lockdown. However, it is well recognised that some children with T1DM can present acutely with rapid onset of ketoacidosis. The increased rate of severe DKA at presentation serves to emphasise the importance of the ongoing provision of public health campaigns to raise awareness of the symptoms of T1DM amongst parents/caregivers¹⁸.

Overall, TDI for CCs was stable between the three time periods. Consistent with previously published evidence¹¹, the TDI for leukaemia was shorter than for CNS tumours, suggesting that the COVID pandemic has had little impact on this pattern.

A large cross-sectional survey of the impact of the pandemic on CC care from the Paediatric Oncology East and Mediterranean Group, reported that some centres noticed that all newly diagnosed patients experienced delays in diagnosis.¹⁹ This was thought to be due to: 1) patients refusing to present for essential visits for fear of contracting COVID-19; 2) hospital staff being relocated to other areas; and 3) governmental decisions impacting upon the availability of public transport and freedom of travel. Although, in the UK during the first lockdown the availability of public transport was decreased and in some tertiary oncology centres paediatric hospital staff were redeployed, our data does not support a similar situation in the participating centres.

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

10% of new CC diagnoses in this study required intensive care within seven days of admission; the majority of these had CNS tumours, most likely due to the requirement for early neurosurgery. From this we infer that patients diagnosed during the pandemic were not more unwell than if they had been diagnosed earlier. We recognise that intensive care admission resulting from treatment can occur in the early stages post-diagnosis.²⁰ Consequently, using intensive care admission may overestimate initial disease severity. Reassuringly, a CCLG study reported that children with cancer and SARS-CoV-2 infection do not appear at increased risk of severe infection compared to the general paediatric population²¹.

Whilst there was variability between units, there was evidence of a shift towards first presentations to ED from primary care, for CC and T1DM patients. Whilst we did not identify statistically significant changes, we recommend that each treatment centre evaluate any change in how their services have been accessed during the pandemic, to assist in future service planning.

There are a number of limitations to this study. Only four centres in the UK were involved, therefore the study lacked the ability to detect national variations in patterns of presentation. Whilst the analysis was prospectively designed, the data collection was retrospective. We cannot exclude the possibility of incomplete areas of data collection given that some of the children in the service evaluation will have been treated in more than one centre. We believe that this effect is both random and minimal across the centres. Given the resources available for this service evaluation we elected to collect comparison data for one year prior to the pandemic (2019). However, we recognise that fluctuation occurs and a longer period of pre-pandemic data collection would have provided greater insight into this variation. It was reassuring however that the incident cases of CC across the UK as a whole remained stable from 2013-17²².

In view of the fluid situation of the pandemic, data collection was completed in July 2020 as we believed that timely presentation could inform local practice. We will continue data collection to account for the diagnostic lag for specific diseases including brain tumours. Data collection at a more comprehensive national level would also provide greater clarity on

diagnostic intervals. Furthermore, it is important to establish whether subsequent public health measures have impacted the TDI in the context of an evolving backlog of patient referrals across the UK.

Conclusions

This project was born out of a desire to understand the impact that COVID-19 was having on life-changing childhood diagnoses. Our findings suggest that public health measures, imposed to control the spread of the pandemic during the first lockdown in the UK, were not associated with delayed diagnosis of CC or T1DM at participating centres. This is good news in the context of a pandemic that has been harmful to children's health and wellbeing in many other ways. We believe that our study can play a key role in allaying parental and professional concern.

Acknowledgement

The authors would like to thank Dr Bob Phillips for his valuable input into the Caldicott approval application process and project set up at Leeds Teaching Hospitals NHS Trust.

REFERENCES

1. Thornton J. Covid-19: A&E visits in England fall by 25% in week after lockdown. *BMJ* 2020; **369**: m1401.
2. Williams TC, MacRae C, Swann OV, et al. Indirect effects of the COVID-19 pandemic on paediatric healthcare use and severe disease: a retrospective national cohort study. *Archives of Disease in Childhood* 2021; archdischild-2020-321008.
3. Liguoro I, Pilotto C, Vergine M, Pusiol A, Vidal E, Cogo P. The impact of COVID-19 on a tertiary care pediatric emergency department. *European Journal of Pediatrics* 2021.
4. Lynn RM, Avis JL, Lenton S, Amin-Chowdhury Z, Ladhani SN. Delayed access to care and late presentations in children during the COVID-19 pandemic: a snapshot survey of 4075 paediatricians in the UK and Ireland. *Archives of Disease in Childhood* 2021; **106**(2): e8.
5. Weller D, Vedsted P, Rubin G, et al. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. *British journal of cancer* 2012; **106**(7): 1262-7.
6. Cancer Research UK. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers/incidence#heading=Zero> (accessed 27/8 2020).
7. CCLG ChildCancerSmart. <https://www.cclg.org.uk/ChildCancerSmart> (accessed 27/8 2020).
8. Lai AG, Pasea L, Banerjee A, et al. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. *BMJ Open* 2020; **10**(11): e043828.
9. Sud A, Torr B, Jones ME, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. *The Lancet Oncology* 2020; **21**(8): 1035-44.
10. Evans NT, Wakefield CE, McLoone JK, Cohn RJ. Familial diagnostic experiences in paediatric oncology. *Br J Cancer* 2015; **112**(1): 20-3.
11. Lethaby CD, Picton S, Kinsey SE, Phillips R, van Laar M, Feltbower RG. A systematic review of time to diagnosis in children and young adults with cancer. *Arch Dis Child* 2013; **98**(5): 349-55.
12. Rabbone I, Schiaffini R, Cherubini V, Maffei C, Scaramuzza A. Has COVID-19 Delayed the Diagnosis and Worsened the Presentation of Type 1 Diabetes in Children? *Diabetes Care* 2020; **43**(11): 2870-2.
13. Unsworth R, Wallace S, Oliver NS, et al. New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the UK. *Diabetes Care* 2020; **43**(11): e170-e1.
14. BSPED Interim Guideline for the Management of Children and Young People under the age of 18 years with Diabetic Ketoacidosis. <https://www.bsped.org.uk/media/1798/bsped-dka-guideline-2020.pdf>.
15. Isba R, Edge R, Jenner R, Broughton E, Francis N, Butler J. Where have all the children gone? Decreases in paediatric emergency department attendances at the start of the COVID-19 pandemic of 2020. *Archives of Disease in Childhood* 2020; **105**(7): 704-.
16. Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. *Lancet Child Adolesc Health* 2020; **4**(5): e10-e1.

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

17. Ng SM, Woodger K, Regan F, et al. Presentation of newly diagnosed type 1 diabetes in children and young people during COVID-19: a national UK survey. *BMJ Paediatrics Open* 2020; **4**(1): e000884.
18. The 4 Ts Campaign. https://www.diabetes.org.uk/get_involved/campaigning/4-ts-campaign.
19. Saab R, Obeid A, Gachi F, et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on pediatric oncology care in the Middle East, North Africa, and West Asia region: A report from the Pediatric Oncology East and Mediterranean (POEM) group. *Cancer* 2020; **126**(18): 4235-45.
20. Piastra M, Fognani G, Franceschi A, Oncology IINIFICIP. Pediatric Intensive Care Unit admission criteria for haemato-oncological patients: a basis for clinical guidelines implementation. *Pediatr Rep* 2011; **3**(2): e13.
21. Millen GC, Arnold R, Cazier JB, et al. Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project. *Br J Cancer* 2020.
22. Cancer registration statistics, England. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancerregistrationstatisticscancerregistrationstatisticsengland> (accessed 24/07/2020).

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

Table 1 Summary of incident childhood cancer patient characteristics (n=253)

	Total (n=253)		Jan -Jun 2019 (n=138)		Jan-Mar 2020 (n=59)		Apr-Jun 2020 (n=56)		p-value
	n	CoI%	n	CoI%	n	CoI%	n	CoI%	
Gender									0.150
Male	162	64%	81	59%	41	69%	40	71%	
Female	91	36%	57	41%	18	31%	16	29%	
Age									0.963
Under 5	99	39%	53	38%	25	43%	21	38%	
5-11	92	37%	52	38%	19	33%	21	38%	
12+	61	24%	33	24%	14	24%	14	25%	
BAME background									0.945
No	198	78%	107	78%	47	80%	44	79%	
Yes	55	22%	31	22%	12	20%	12	21%	
COVID isolation/shielding									
No	250	99%	138	100%	59	100%	53	95%	
Yes	3	1%	0	0%	0	0%	3	5%	
Tumour type									0.273
Leukaemia	69	27%	33	24%	17	29%	19	34%	
CNS tumour	74	29%	48	35%	14	24%	12	21%	
All other tumour types	110	43%	57	41%	28	47%	25	45%	
ICU stay									0.275
No	223	88%	120	87%	55	93%	48	86%	
Yes	26	10%	17	12%	3	5%	6	11%	
Not known	4	2%	1	1%	1	2%	2	4%	
HCP visits before diagnosis									0.569
3 or less	152	60%	82	59%	40	68%	30	54%	
4-6	64	25%	38	28%	12	20%	14	25%	
7-9	21	8%	11	8%	3	5%	7	13%	
10 or more	16	6%	7	5%	4	7%	5	9%	


Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

Table 2 Summary of incident T1DM patient characteristics (n=187)


	Total (n=187)		Jan-Jul 2019 (n=98)		Jan-Mar 2020 (n=43)		Apr-Jul 2020 (n=46)		p-value
	n	Col%	n	Col%	n	Col%	n	Col%	
Gender									0.718
Male	90	48%	46	47%	23	53%	21	46%	
Female	97	52%	52	53%	20	47%	25	54%	
Age									0.174
Under 5	32	17%	22	22%	5	12%	5	11%	
5-11	87	47%	43	44%	18	42%	26	57%	
12+	68	36%	33	34%	20	47%	15	33%	
BAME background									0.484
No	168	90%	87	89%	41	95%	40	89%	
Yes	18	10%	11	11%	2	5%	5	11%	
COVID isolation/shielding									0.012
No	183	98%	98	100%	43	100%	42	91%	
Yes - self-isolation	3	2%	0	0%	0	0%	3	7%	
Yes - shielding	1	1%	0	0%	0	0%	1	2%	
DKA									0.624
No	112	60%	59	61%	26	60%	27	59%	
Mild/Moderate	46	25%	25	26%	12	28%	9	20%	
Severe	28	15%	13	13%	5	12%	10	22%	
Ventilation									0.607
No	182	97%	94	96%	43	100%	45	98%	
Yes	5	3%	4	4%	0	0%	1	2%	
ITU stay									0.625
No	169	91%	90	92%	39	93%	40	87%	
Yes	17	9%	8	8%	3	7%	6	13%	
HCP visits before diagnosis									0.673
1	164	92%	87	92%	37	95%	40	89%	
>1	15	8%	8	8%	2	5%	5	11%	

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic


(a) Childhood cancer



(b) Childhood cancer



(c) T1DM



(d) T1DM




Figure 1 Number of newly diagnosed of childhood cancer and T1DM cases between Jan-Jul 2020 compared to the corresponding period in 2019. (a) (c) data covers all participating centres contributing data to the project by month. Shaded areas indicate national lockdown months (b) (d) data by individual centre over the periods January to June/July in 2019 and 2020.

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic






Figure 2 Time to diagnosis for paediatric oncology. **(a)** Total diagnostic interval (TDI): interval between first symptom onset to diagnosis. **(b)** Patient interval (PI): time from initial symptom onset to first presentation to healthcare. **(c)** System interval (SI): time between first presentation to healthcare to diagnosis

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic

(a) Total diagnostic interval (TDI)



(b) Patient interval (PI)



(c) System interval (SI)




Figure 3 Time to diagnosis for childhood cancer for leukaemia, CNS tumour and all other tumour types combined. (a) Total diagnostic interval (TDI): interval between first symptom onset to diagnosis. (b) Patient interval (PI): time from initial symptom onset to first presentation to healthcare. (c) System interval (SI): time between first presentation to healthcare to diagnosis

Diagnostic intervals of childhood cancer and T1DM during COVID-19 pandemic




Figure 4 Time to diagnosis of incident T1DM cases between January and July 2020 and corresponding period in 2019. (a) Total diagnostic interval (TDI): interval between first symptom onset to diagnosis. (b) Patient interval (PI): time from initial symptom onset to first presentation to healthcare.